United Therapeutics CORPORATION

A Balanced, Value-creating Biotechnology Model with 6 Therapeutic Platforms

1

REMODULIN® (treprostinil) Injection

2

TYVASO® (treprostinil) INHALATION SOLUTION

3

orenitram® treprostinil EXTENDED-RELEASE TABLETS

4



NCE[1] / Novel Biologics

5

Unituxin® (dinutuximab) Injection

Dinutuximab

6

Organ Manufacturing

(1) NCE = New Chemical Entities.

MEDICINES FOR LIFE®

United Therapeutics CORPORATION

NASDAQ **UTHR** **2019 FINANCIALS** Product Revenue **~$1.45B**[1] Revenue /Employee **~$1.6M**

Founded **1996** HQ ① **Research Triangle Park, NC** ② **Silver Spring, MD** Employees **>900**

Commercial Products and Services[3]

Products:

REMODULIN® (treprostinil) Injection

TYVASO® (treprostinil) INHALATION SOLUTION

orenitram® treprostinil EXTENDED-RELEASE TABLETS

Unituxin® (dinutuximab) Injection

Services:

XPS™

Therapeutic Platforms **6** ① Remodulin® ② Tyvaso® ③ Orenitram® ④ NCE[2] / Novel Biologics ⑤ Dinutuximab ⑥ Organ Manufacturing

NEAR-term pipeline	*Clinical Trial*	*Status*	*Therapeutic Platform*
REMUNITY™ Pre-filled, SubQ System	–	FDA Cleared[4] U.S. launch targeted July 2020	①
TREVYENT® Pre-filled, Pre-programmed Single-use Treprostinil Pump	–	NDA Under FDA Review 2020 PDUFA Date	①
TYVASO® PH WHO Group 3 (ILD)	INCREASE	All endpoints met[5] FDA label supplement to be filed mid-2020	②
IMPLANTABLE SYSTEM FOR REMODULIN®	–	FDA Approved[6]	①
TECHNOSPHERE® Inhaled DPI Treprostinil for PAH	BREEZE	Phase III	②

MEDIUM-term pipeline	*Clinical Trial*	*Status*	*Therapeutic Platform*
TYVASO® PH WHO Group 3 (COPD)	PERFECT	Phase III	②
ORENIPRO® Once-daily, Oral Treprostinil Prodrug	–	Pre-clinical	③
REMOPRO™ Pain-less SubQ for PAH	–	Phase I	①
UNEXISOME™ (exosomes)	-	Phase I	④
RALINEPAG IP Receptor Agonist for PAH	ADVANCE STUDIES	Phase III	④
AURORA-GT™ eNOS Gene Therapy for PAH	SAPPHIRE	Phase II/III	④
LNG01[7] Wnt Pathway Inhibitor for Idiopathic Pulmonary Fibrosis (IPF)	–	Phase I	④

(1) As reported in UT's annual report on Form 10-K for the period ended December 31, 2019. **(2)** NCE=New Chemical Entities. **(3)** Commercial products also include Adcirca® which went generic in August 2018. **(4)** FDA clearance of pharmacy-filled version. **(5)** Tyvaso increased six-minute walk distance by 21 meters versus placebo (p=0.0043, Hodges-Lehmann estimate) after 16 weeks of treatment. Additionally, INCREASE met all secondary endpoints (i.e., Change in NT-proBNP from baseline to week 16; Time to first clinical worsening event; Change in peak 6MWD from baseline to week 12; Change in trough 6MWD from baseline to week 15). **(6)** U.S. launch pending satisfaction of further regulatory requirements by Medtronic. **(7)** Program formerly named SM04646.